Latest filing published 05 Apr 2022 for Genocea Biosciences, INC., €1,097.
Filing timeline
BuySaleInsider track record
Girish N. Aakalu: trading record in brief
Girish N. Aakalu (senior executive) discloses dealings in Genocea Biosciences, Inc. to SEC (Form 4). We count 6 filings; the first trade dates from 2 April 2020 and the latest from 4 April 2022.
No open-market purchase appears, only 2 sales worth €3,500. Other entries cover 4 share grants. Since January 2022: no purchases and 2 sales on the market.
The latest filing, published on 5 April 2022, reports an open-market sale of €1,097 in Genocea Biosciences, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Girish N. Aakalu
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 963 shares@ US$1.25100.0% of flowCommon StockSEC:0001457612-22-000042:0
- 2,397 shares@ US$1.100.1% of flowCommon StockSEC:0001457612-22-000024:1
- 31,250 shares0Common StockSEC:0001457612-22-000024:0
- 31,250 shares0Common StockSEC:0001457612-21-000036:0
- 6,623 shares0Common StockSEC:0001457612-20-000077:0
- 12,299 shares0Common StockSEC:0001457612-20-000027:0
6 of 6 declarations
